Exodus Point Capital Management, LP Atara Biotherapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$1.41 - $2.31 $96,988 - $158,895	68,786 Added 16.46%	486,668 $720,000
Q2 2023 Aug 10, 2023	BUY	$1.5 - $3.04 $216,597 - $438,969	144,398 Added 52.8%	417,882 $673,000
Q1 2023 May 11, 2023	BUY	$2.8 - $5.46 $594,241 - $1.16 Million	212,229 Added 346.47%	273,484 $793,000
Q4 2022 Feb 13, 2023	BUY	$2.85 - $5.18 $3,742 - $6,801	1,313 Added 2.19%	61,255 $201,000
Q3 2022 Nov 10, 2022	BUY	$2.85 - $8.73 $170,834 - $523,293	59,942 New	59,942 $227,000

Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $149,131 - $222,640	-12,438 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $160,325 - $206,222	12,438 New	12,438 $193,000
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $388,388 - $574,814	-27,742 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $351,491 - $727,672	27,742 New	27,742 $545,000
Q1 2020 May 15, 2020	SELL	$5.69 - $17.78 $70,794 - $221,218	-12,442 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $135,493 - $208,901	12,442 New	12,442 $205,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.